Non-Viral, Specifically Targeted CAR-T Cells Achieve High Safety and Efficacy in B-NHL

Researchers successfully developed a two-in-one approach to generate non-viral, gene-specific targeted CAR-T cells through CRISPR–Cas9. Using the optimized protocol, they demonstrated feasibility in a preclinical study by inserting an anti-CD19 CAR cassette into the AAVS1 safe-harbour locus.